
The Australian Therapeutic Goods Administration (TGA) has granted approval for Fampyra™, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.
Fampyra demonstrated efficacy in people with all four majortypes of MS (relapsing remitting, secondary progressive, progressive relapsing and primary progressive). Fampyra can be used alone or with existing MS therapies, including immunomodulator drugs..... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1310